30 years of historical data (1996–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Celldex Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.8B | $1.6B | $1.9B | $2.1B | $1.7B | $519M | $32M | $31M | $365M | $359M |
| Enterprise Value | $2.0B | $1.8B | $1.6B | $1.9B | $2.1B | $1.6B | $479M | $25M | $12M | $331M | $317M |
| P/E Ratio → | -7.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1334.98 | 1204.09 | 231.80 | 279.16 | 886.63 | 356.16 | 70.00 | 9.05 | 3.28 | 28.65 | 52.96 |
| P/B Ratio | 3.80 | 3.43 | 2.18 | 4.48 | 6.41 | 3.95 | 2.48 | 0.34 | 0.25 | 1.54 | 1.35 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1186.40 | 228.31 | 274.48 | 875.86 | 348.40 | 64.56 | 6.93 | 1.21 | 26.00 | 46.71 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Celldex Therapeutics, Inc. earns an operating margin of -19160.0%. Operating margins have compressed from -2245.3% to -19160.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -40.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -2229.8% | -1614.5% | -3389.9% | -1046.2% | -473.4% | -1094.3% | -596.7% | -654.7% | -1403.5% |
| Operating Margin | -19160.0% | -19160.0% | -2778.9% | -2245.3% | -4889.0% | -1531.8% | -854.1% | -1540.2% | -1640.1% | -953.7% | -1958.7% |
| Net Profit Margin | -17253.3% | -17253.3% | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.6% | -40.6% | -26.8% | -37.4% | -30.1% | -22.4% | -39.4% | -46.7% | -83.9% | -37.1% | -46.3% |
| ROA | -37.6% | -37.6% | -25.1% | -34.6% | -28.2% | -20.7% | -33.3% | -36.5% | -64.1% | -26.6% | -35.7% |
| ROIC | -35.2% | -35.2% | -26.1% | -33.2% | -25.3% | -19.3% | -37.2% | -43.3% | -76.5% | -42.8% | -44.8% |
| ROCE | -44.7% | -44.7% | -32.9% | -40.2% | -30.2% | -21.9% | -38.1% | -43.2% | -72.6% | -38.2% | -40.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $29M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 | 0.03 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -0.03 | -0.08 | -0.08 | -0.09 | -0.19 | -0.08 | -0.16 | -0.14 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($29M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
Celldex Therapeutics, Inc.'s current ratio of 10.49x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.87x to 10.49x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.49 | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
| Quick Ratio | 10.49 | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
| Cash Ratio | 10.17 | 10.17 | 18.36 | 13.55 | 16.39 | 24.70 | 13.69 | 5.51 | 7.46 | 5.03 | 5.39 |
| Asset Turnover | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.06 | 0.04 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 490.32 | 36.40 | 240.12 | 53.74 | 13.50 | 88.67 | 124.12 | 121.00 | 53.85 | 95.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Celldex Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $67M | $64M | $48M | $47M | $43M | $30M | $15M | $10M | $9M | $7M |
Compare CLDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CLDXYou | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CLDX stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonCelldex Therapeutics, Inc.'s current P/E ratio is -7.7x. This places it at the 50th percentile of its historical range.
Celldex Therapeutics, Inc.'s return on equity (ROE) is -40.6%. The historical average is -74.2%.
Based on historical data, Celldex Therapeutics, Inc. is trading at a P/E of -7.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Celldex Therapeutics, Inc. has 100.0% gross margin and -19160.0% operating margin.